Israel’s Regentis Biomaterials is shortly to conduct a Phase III clinical study of GelrinC, a new treatment for focal cartilage defects in the knee. GelrinC is poured into the lesion in a minimally invasive procedure and converted into a solid implant using ultra-violet light.
A remedy for damaged knee cartilage
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.